{"id":10266,"date":"2026-07-15T11:50:26","date_gmt":"2026-07-15T09:50:26","guid":{"rendered":"https:\/\/cleanpeptides.eu\/pt-141-doseringsguide\/"},"modified":"2026-07-15T11:50:26","modified_gmt":"2026-07-15T09:50:26","slug":"pt-141-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/pt-141-doseringsguide\/","title":{"rendered":"PT-141 (Bremelanotid) doseringsguide"},"content":{"rendered":"<p><em>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide samler produktinformation og uafh\u00e6ngigt undervisningsmateriale som forskningsreference; den udg\u00f8r ikke l\u00e6gelig r\u00e5dgivning.<\/em><\/p>\n<h2>Hvad er PT-141?<\/h2>\n<p>PT-141 (bremelanotid) er FDA-godkendt til hypoaktiv seksuel lystforstyrrelse (HSDD) hos pr\u00e6menopausale kvinder og markedsf\u00f8res som Vyleesi. I mods\u00e6tning til PDE5-h\u00e6mmere (Viagra, Cialis), der virker p\u00e5 blodgennemstr\u00f8mningen, virker PT-141 centralt i hjernen via melanocortin-4-receptorer (MC4R) i hypothalamus for at \u00f8ge seksuel lyst og ophidselse. Det er en cyklisk heptapeptid-analog af alfa-MSH. Doseringen er k\u00f8nsspecifik med strenge frekvensgr\u00e6nser (maks. 8 doser\/m\u00e5ned).<\/p>\n<h2>N\u00f8gleegenskaber<\/h2>\n<ul>\n<li>Central mekanisme \u2014 virker i hjernen, ikke p\u00e5 blodkarrene.<\/li>\n<li>MC4R-agonist \u2014 \u00f8ger seksuel lyst og ophidselse.<\/li>\n<li>Begge k\u00f8n \u2014 FDA-godkendt kun til pr\u00e6menopausale kvinder med HSDD.<\/li>\n<li>Dosering efter behov \u2014 45+ min f\u00f8r forventet aktivitet.<\/li>\n<li>Frekvensgr\u00e6nse \u2014 maks. 8 doser\/m\u00e5ned, h\u00f8jst 1 pr. 24 timer.<\/li>\n<li>Afledt af Melanotan II \u2014 modificeret til at fokusere p\u00e5 seksuel funktion med reduceret solbrunings-effekt.<\/li>\n<\/ul>\n<h2>Dosering \u2014 Kvinder (FDA-godkendt)<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Parameter<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protokol<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Dosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,75 mg SC<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Timing<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">45 minutter f\u00f8r forventet aktivitet<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Maksimum pr. dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1 dosis pr. 24 timer<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">M\u00e5nedlig gr\u00e6nse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">8 doser om m\u00e5neden<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Inds\u00e6ttelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">45\u201360 minutter<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Varighed<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">4\u20136+ timer<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Dosering \u2014 M\u00e6nd (off-label)<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Parameter<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protokol<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Dosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1,0\u20132,0 mg SC<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Timing<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1\u20132 timer f\u00f8r forventet aktivitet<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Maksimum pr. dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1 dosis pr. 24 timer<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">M\u00e5nedlig gr\u00e6nse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">8\u201310 doser om m\u00e5neden<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Inds\u00e6ttelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1\u20132 timer (langsommere end hos kvinder)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Varighed<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">4\u20136+ timer<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Rekonstituering og dosering (med de medf\u00f8lgende 3 mL)<\/h2>\n<p>Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL.<\/p>\n<p><strong>Hurtig formel:<\/strong> koncentration = h\u00e6tteglassets styrke \u00f7 3 mL; enheder der skal tr\u00e6kkes = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglassets styrke (mg).<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Koncentration<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1,75 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">2 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">10 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,33 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">30 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">52,5 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">60 u<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Opbevar det rekonstituerede produkt i k\u00f8leskab (2\u20138 \u00b0C) og brug det inden for 28-30 dage.<\/p>\n<h2>Injektionsguide<\/h2>\n<p>Vask h\u00e6nderne og g\u00f8r materialet klar. Aft\u00f8r h\u00e6tteglassets prop og lad den t\u00f8rre. Tr\u00e6k din dosis op og bank boblerne ud. V\u00e6lg maven eller l\u00e5ret, og skift mellem stederne. Rens stedet og lad det t\u00f8rre. Injicer subkutant i en knebet fold ved 45\u00b0. Bortskaf i en kanylebeholder. Injicer 45 min (kvinder) til 1\u20132 t (m\u00e6nd) f\u00f8r den forventede aktivitet.<\/p>\n<h2>Hvorfor der er frekvensgr\u00e6nser<\/h2>\n<ul>\n<li><strong>Blodtryk<\/strong> \u2014 PT-141 giver forbig\u00e5ende stigninger; hyppig dosering \u00f8ger den kumulative kardiovaskul\u00e6re belastning.<\/li>\n<li><strong>Kvalme<\/strong> \u2014 rammer 40 % af brugerne; for hyppig dosering forv\u00e6rrer sv\u00e6rhedsgraden.<\/li>\n<li><strong>MC-receptor-desensibilisering<\/strong> \u2014 gentagen MC4R-aktivering reducerer effekten; afstand bevarer responsen.<\/li>\n<li><strong>Hyperpigmentering<\/strong> \u2014 resterende MC1R-aktivitet g\u00f8r, at hyppig brug risikerer fokal m\u00f8rkfarvning.<\/li>\n<\/ul>\n<p>Gr\u00e6nsen p\u00e5 8 doser\/m\u00e5ned er en sikkerhedsgr\u00e6nse, ikke et m\u00e5l. Mange finder 2\u20134 doser\/m\u00e5ned tilstr\u00e6kkeligt.<\/p>\n<h2>Kombinationer (stacking)<\/h2>\n<p><strong>PT-141 + PDE5-h\u00e6mmere (m\u00e6nd)<\/strong> \u2014 central + perifer: PT-141 1,0\u20132,0 mg SC (central lyst) + sildenafil 25\u201350 mg oralt (perifer blodgennemstr\u00f8mning). Begge p\u00e5virker blodtrykket \u2014 t\u00e6t overv\u00e5gning, reducerede PDE5-doser, kun under l\u00e6geligt tilsyn. PT-141 bruges efter behov med strenge frekvensgr\u00e6nser og stakker ikke meningsfuldt med helende peptider, GH-sekretagoger eller kosmetiske peptider. Bedst brugt alene.<\/p>\n<h2>Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p>Veldokumenteret fra fors\u00f8g (1.200 deltagere). Meget almindelige (\u226510 %): kvalme (40 %, topper ved 1\u20132 t, aftager med brug), r\u00f8dmen (20 %), hovedpine (11 %). Almindelige (1\u201310 %): reaktioner ved injektionsstedet, hedeture. Mindre almindelige (&lt;1 %): forbig\u00e5ende blodtryksstigning, hyperpigmentering.<\/p>\n<p><strong>H\u00e5ndtering af kvalme:<\/strong> let snack f\u00f8r injektion; ondansetron 4\u20138 mg 30 min f\u00f8r; start med en lavere dosis; kvalme aftager med gentagen brug.<\/p>\n<p><strong>Kontraindikationer:<\/strong> ukontrolleret hypertension; hjerte-kar-sygdom; graviditet (kategori X); nedsat leverfunktion.<\/p>\n<p><strong>Interaktioner:<\/strong> naltrexon (kontraindiceret \u2014 reducerer effekten); blodtryksmedicin; PDE5-h\u00e6mmere (l\u00e6geligt tilsyn, reducerede doser). FDA-godkendt (Vyleesi); IKKE p\u00e5 WADA&#8217;s forbudsliste.<\/p>\n<h2>Almindelige fejl<\/h2>\n<ul>\n<li>At bruge det dagligt som en almindelig medicin (strengt efter behov, maks. 8\/m\u00e5ned).<\/li>\n<li>Ikke at give nok tid til inds\u00e6ttelse.<\/li>\n<li>At overskride 8 doser om m\u00e5neden.<\/li>\n<li>At starte p\u00e5 2,0 mg uden at teste tolerance.<\/li>\n<li>At bruge det som erstatning for at tage fat p\u00e5 de underliggende problemer.<\/li>\n<li>At ignorere blodtryksoverv\u00e5gning.<\/li>\n<\/ul>\n<h2>Vigtigste pointer<\/h2>\n<ul>\n<li>FDA-godkendt (Vyleesi) til pr\u00e6menopausale kvinder med HSDD.<\/li>\n<li>Standarddosis 1,75 mg SC, \u226545 min f\u00f8r aktivitet. Maks. 8 doser\/m\u00e5ned.<\/li>\n<li>Virker centralt via MC4R \u2014 forskelligt fra Viagra\/Cialis.<\/li>\n<li>~40 % kvalme; h\u00e5ndt\u00e9r med en snack, lavere dosis eller ondansetron.<\/li>\n<li>Ikke et dagligt peptid; kontraindiceret med naltrexon, ukontrolleret hypertension og graviditet.<\/li>\n<\/ul>\n<h2>Download og relaterede ressourcer<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/13-PT-141-Dosage-Guide-Clean-Peptides.pdf\">\ud83d\udcc4 Download den fulde PDF-guide<\/a><\/p>\n<p><a href=\"https:\/\/cleanpeptides.eu\/product\/pt-141-10-mg\/\">PT-141 10 mg<\/a><\/p>\n<h2>Referencer<\/h2>\n<ol>\n<li>Kingsberg SA, et al. \u00abBremelanotide for HSDD: Two Randomized Phase 3 Trials (RECONNECT).\u00bb Obstet Gynecol. 2019;134(5):899-908.<\/li>\n<li>Diamond LE, et al. \u00abEffect on subjective sexual response by bremelanotide (PT-141).\u00bb J Sex Med. 2006;3(4):628-638.<\/li>\n<li>Rosen RC, et al. \u00abBremelanotide: a new pharmacotherapy for HSDD.\u00bb Expert Opin Investig Drugs. 2017;26(9):1049-1057.<\/li>\n<li>AMAG Pharmaceuticals. \u00abVyleesi (bremelanotide) Prescribing Information.\u00bb FDA.gov. 2019.<\/li>\n<li>Molinoff PB, et al. \u00abPT-141: a melanocortin agonist for sexual dysfunction.\u00bb Ann N Y Acad Sci. 2003;994:96-102.<\/li>\n<\/ol>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10266","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10266"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10266\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}